[UBS: Raises Moderna's Target Price from $50 to $150] BlockBeats News, August 20, UBS announced that it has raised Moderna's (MRNA.O) target price from $50 to $150. Previously reported, Moderna, in collaboration with Merck, achieved significant success in the Phase 3 clinical trial of its personalized mRNA cancer vaccine for high-risk melanoma. This is the world's first mRNA cancer therapy proven effective in a large-scale Phase 3 trial. Following the announcement, Moderna's stock price surged nearly 177% in a single day.